uniQure gains on Factor IX activity data for hemophilia B gene therapy

uniQure N.V. (NASDAQ:QURE) added $8.13 (36%) to $30.93 on Thursday after reporting that all three patients who received hemophilia B gene therapy AMT-061 in a dose-confirmation Phase IIb trial achieved and sustained therapeutic levels of Factor IX activity. The company has started enrollment in the Phase

Read the full 467 word article

User Sign In